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Abstract 
Background: Pancreatic Carcinoma (PC) is a lethal disease with a poor prognosis. Pancreatic 
Carcinoma is characterized by a desmoplastic, highly heterogeneous and immune-suppressive 
microenvironment that hinders antitumour immunity. The aim of this study is to investigate the 
correlation between PC patient prognosis and the presence of tumour infiltrating lymphocytes and 
expression of 521 immune system genes.  
Materials and Method: Fresh PC specimens were obtained from patients (n=12) undergoing 
surgical resection at the Department of Medical, Surgical & Health Sciences, Cattinara Teaching 
Hospital, Trieste University, between 2005 and 2015. Prognosis of primary PC patients was 
determined using clinical data and Kaplan-Meier curves. Overall survival (OS) was measured from 
the time of surgery to the time of death or the last follow up visit. A more in-depth analysis of the 
12 patients revealed two groups with different disease free survival (DFS) and/or OS: six patients 
with an OS between 25 and 66 months were classified as “good cases”, while six with OS between 
2 and 9 months or DFS between 1 and 2 months were classified as “worse cases”. Intratumoural 
CD3+, CD8+, and CD20+ lymphocytes were examined by immunohistochemistry. The results were 
correlated with gene expression profile using the digital multiplexed NanoString nCounter analysis 
system (NanoString Technologies, Seattle, WA, USA).  
Results: Our data showed that the CD3 level was statistically higher in the good prognosis group 
compared to the worse prognosis group (p=0.0267). Three primary PC patients with a good 
prognosis and three with a worse prognosis were then chosen for mRNA analysis by PanCancer 
Immune Profile Panel multiplex gene expression analysis. Twenty immune system genes were 
significantly differentially expressed in patients with a good prognosis relative to patients with a 
worse prognosis: TLR2 and TLR7 (Toll-like receptor superfamily); CD4, CD37, FOXP3, PTPRC 
(B cell and T cell signalling); IRF5, IRF8, STAT1, TFE3 (transcription factors); ANP32B, CCND3 
(cell cycle); BTK (B cell development); TNF, TNFRF1A (TNF superfamily); HCK (leukocyte 
function); C1QA (complement system); BAX, PNMA1 (apoptosis); IKBKE (NF B pathway). 
Differential expression was more than twice log 2 for TLR7, TNF, C1QA, FOXP3, and CD37.  
Conclusion: The key findings from this study, that longer-surviving PC patients had higher levels 
of intratumoural TILs and overexpressed five immune markers (TLR7, TNF, C1QA, FOXP3, 
CD37), could have two main uses. Together with an assessment of TIL levels, such an immune 
system gene panel constitutes a potential prognostic tool to permit a risk-based stratification of 
pancreatic tumour patients into personalized treatment protocols towards improving the current 
abysmal clinical outcome of these patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Pancreatic carcinoma (PC) is the fourth most common cause of cancer-related death 
among men (after lung, prostate, and colorectal cancer) and  women (after lung, 
breast, and colorectal cancer). Pancreatic cacrinoma is linked to cigarette smoking, 
exposure to chemicals, heavy metals and heavy alcohol consumption. Finally, body 
mass index (BMI) and diabetes are also usually reported as risk factor for PC. The 
symptoms of PC do not usually appear in the disease's early stages, and they are not 
individually distinctive to the disease. The symptoms at diagnosis vary according to 
the location of the cancer in the pancreas, which anatomists divide (from left to right 
on most diagrams) into the thick head, the neck, and the tapering body, ending in the 
tail. However, regardless the location, the symptoms of PC can include weight loss, 
jaundice, floating stools, pain, dyspepsia, nausea, vomiting, and occasionally 
pancreatitis; however, no early warning signs of have been established. Medical 
imaging techniques, such as computed tomography (CT scan) and endoscopic 
ultrasound (EUS) are used both to confirm the diagnosis and to help decide whether 
the tumor can be surgically removed. A biopsy by fine needle aspiration, often guided 
by endoscopic ultrasound, may be used where there is uncertainty over the diagnosis, 
but a histologic diagnosis is not usually required for removal of the tumor by surgery 
to go ahead. PC can be treated with surgery, radiotherapy, chemotherapy, palliative 
care, or a combination of these. Treatment options are based on the cancer stage. 
Surgery is the only treatment that can cure pancreatic adenocarcinoma, and may also 
be done to improve quality of life without the potential for cure. Pain management 
and medications to improve digestion are sometimes needed. Early palliative care is 
recommended even for those receiving treatment that aims for a cure.  
Immune cells within the cancer infiltrate may have a role in fighting cancer growth 
via antigen restricted tumouricidal responses or they may promote tumour 
progression by suppressing the immune system. According pathlogical findings, PC 
is characterized by a desmoplastic, highly heterogeneous and immune-suppressive 
microenvironment that hinders antitumour immunity. Based on these findings, the 
relationship between immunity and PC progression has been investigated, therefore, 
the aim of this study is to investigate the correlation between PC patient prognosis 
and the presence of tumour infiltrating lymphocytes and expression of 521 immune 
system genes. 
 
 
 
 
 
 
 
Materials & Methods 
Patients and sample collection 
Fresh PC specimens were obtained from patients undergoing surgical resection at the 
Department of Medical, Surgical & Health Sciences, Cattinara Teaching Hospital, 
Trieste University. Tissue specimens were snap frozen in liquid nitrogen and stored at 
−80˚C. Formalin-fixed, paraffin wax-embedded sections were used for 
immunohistochemical staining. All paraffin wax blocks were confirmed to contain 
tumour tissue by two pathologists, comprising six pancreatic adenocarcinomas with a 
good prognosis and six pancreatic adenocarcinomas with a bad prognosis. The 
following clinical data were collected: patient age, gender, and outcome; the 
presence/ absence of metastasis; tumour location, size, margin status, TNM stage, 
degree of differentiation, invasion degree and location (lymph node, bile 
duct/duodenal serosa, hepatic, portal vein, vascular, perineural), schedule of 
chemotherapy, neoadjuvant and/or adjuvant chemotherapy, chemotherapy toxicity, 
and treatment follow up. Clinical Stadiation of patients ranged from stage IA to III 
but none of them was metastatic and none of them underwent chemotherapy.  
PanCancer Immune Profile Panel multiplex gene expression profiling 
To perform Pan Cancer Immune Profile, in accord with Koti et al, pathologists in our 
department selected and extracted two areas of at least 70% of cellularity from each 
formalin-fixed, paraffin wax-embedded tumour tissues, and total RNA was extracted 
using Qiagen RNeasy (Qiagen Inc., Toronto, ON, Canada) as per the manufacturer’s 
instructions. A NanoDrop ND-100 spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA) was used to measure RNA concentration and purity. All 
RNA samples included in the study passed the quality control requirements (as 
verified by RNA integrity number or OD 260/280 ratio) of the platform. Using 100 
ng total RNA from each sample as input, according to the manufacturer’s 
instructions, the digital multiplexed NanoString nCounter analysis system 
(NanoString Technologies, Seattle, WA, USA) was used for gene expression 
profiling. Tumour RNA samples were analysed using nCounter PanCancer immune 
profile panel consisting of 770 human immune-related genes (Nanostring 
Technologies). In this assay, colour-coded barcodes are used to represent single-
target transcripts in the reaction. An overnight hybridisation reaction was used to 
incorporate the resulting material, carried out by combining 20 ml of nCounter 
Reporter probes in hybridisation buffer, 5 ml of nCounter Capture probes and 5 ml of 
the total RNA sample for a total reaction volume of 30 ml. The hybridisations were 
incubated at 65˚C for 16–20 h. An excess of probes is provided during overnight 
hybridization to ensure that each target finds a probe pair. Target abundance values 
can then be determined through the nCounter Digital Analyzer by counting the 
individual fluorescent barcodes. A high-density scan was performed for each assay 
(encompassing 600 fields of view). After hybridisation, the cartridges were analysed 
in the Digital Analyzer that counts (representing the number of molecules) and 
arranges the barcodes. 
Immunohistochemistry for TILs evaluation 
An automatic stainer (BenchMark ULTRA, Ventana Medical System, Inc.) was used 
for the immunohistochemical test. The antigen was retrieved with cell conditioning 
buffer 1. Next, endogenous peroxidase was inhibited with H2O2 at 3% (Bioptica) for 
10 min. Samples were incubated with primary antibody anti-CD3 (2GV6) (Roche-
Ventana), anti-CD8 (SP57) (Roche-Ventana), Rabbit Monoclonal Pre-diluted 
(0.4μg/mL), for 20 min at 36˚C; anti-CD20 (L26) (Roche-Ventana), Mouse 
Monoclonal Pre-Diluted (0.4μg/mL) for 24 min at 36˚C. The antibody was exposed 
with ultraView Universal DAB Detection Kit (Cat No. 760–500). As counterstain, 
Mayer haematoxylin was used for 4 min. Tumour infiltrating lymphocytes (TIL) 
levels were assessed by two investigators blind to the patients’ clinical-pathological 
data using the standardized method coded in 2015 by the International TILs Working 
Group. TILs were investigated per microscopic field (5X and 10X) and an average 
over ten independent 
regions having the most abundant immunoreactive cells was calculated for each slide. 
Statistical analysis 
A preliminary data exploration was performed. Numerical variables were expressed 
as median and range and were compared by nonparametric tests (Mann–Whitney U-
test). Qualitative data were expressed as frequencies and Immune Profile Panel 
multiplex nanoString Statistical Analyses organized into contingency tables; the 
association between categorical variables was investigated by means of Fisher’s exact 
test or Pearson’s Chi-square. Time-dependent variables were calculated according to 
the Kaplan–Meier method. Overall survival was measured from the time of surgery to 
the time of death or the last follow up visit, disease free survival ere measured from 
time of surgery to first recurrence of disease. Dates of death were obtained from 
patient hospital records or follow up telephone calls. For the entire statistical analysis, 
the significance levels were established at p<0.05. All data were analysed with 
STATA software. 
For NanoString data analysis, nSolver (NanoString Technologies) was used for the 
normalization of raw data as previously reported. The raw NanoString counts were 
initially subjected to normalization for all target RNAs in all samples based on built-
in positive controls. This step accounts for post-hybridization processing, inter-
sample and experimental variation such as hybridization efficiency. The geometric 
mean of each of the controls was calculated, indicating the overall assay efficiency. 
For the mRNA content normalisation, housekeeping genes were then used. To 
facilitate downstream statistical analysis, values < 0 were blanketed and considered 
equal to 1. After initial normalisation steps, data were imported to GraphPad Prism 
(GraphPad Software, Inc., La Jolla, CA, USA) to be processed for statistical analysis. 
Multiple t-tests were performed with correction for multiple comparisons through the 
Sidak–Bonferroni method. A difference in expression with a P-value of ≥ 0.05 was 
considered statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
  
Results 
Characteristics of patients 
From 2005 to 2015, 12 fresh PC specimens of patients undergoing pancreatic surgical 
resection were analyzed. An analysis of the 12 patients revealed two groups with 
different DFS and/or OS: six patients with an OS between 25 and 66 months were 
classified as “good cases”, while six with OS between 2 and 9 months or DFS 
between 1 and 2 months were classified as “worse cases”. Table 1 summarizes the 
clinical-pathological data of the two groups of patients and Figure 1 shows the 
Kaplan-Meier curves for DFS and OS for the two groups of patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 1. Summary of patient clinical-pathological information. 
ECOG: Eastern Cooperative Oncology Group (Performance Status); TNM Stadiation: T=Tumour 
(0-4), N=Nodes (0-2), M=Metastasized (0-1). 
 
 Good cases Worse cases 
Num. Pts 6 6 
Age 65.3 63.8 
Gender   
Male 4 3 
Female 2 3 
ECOG   
0 2 0 
1 2 3 
2 1 2 
Not reported 1 1 
TNM   
T   
T0 0 0 
T1 1 2 
T2 0 4 
T3 4 0 
T4 1 0 
N   
N0 2 2 
N1 4 4 
M   
M0 6 6 
STAGE IA/IIA/IIB/III IB/IIA/IIB 
 
 
 
 
 
 Figure 1. Worse and good prognosis PC patient groups. Kaplan-Meier curves show the difference 
of OS or DFS between two groups of patients: one group with a worse prognosis (“worse”, blue 
line) and the other with a better prognosis (“good”, red line). 
 
 
 Immune-related gene expression analysis in pancreatic adenocarcinomas 
with good versus worse prognosis 
Prognosis of primary PC patients was determined using clinical data and Kaplan-
Meier curves (Figure 1). Three primary PC patients with a good prognosis and three 
with a worse prognosis were then chosen for mRNA analysis by PanCancer Immune 
Profile Panel multiplex gene expression analysis. Figure 2 shows the differential 
gene expression. Among the immune system genes showing statistically significant 
(p <0.01) differential expression between pancreatic adenocarcinoma with a good and 
worse prognosis, differential expression of TLR7, TNF, C1QA, FOXP3, and CD37 
was at least twice log 2: +2.76 log 2 ± 0.58 (p <0.00896), +2.39 log 2 ± 0.389 (p 
<0.00356), +2.19 log 2 ± 0.43 (p <0.00697), +2.07 log 2 ± 0.372 (p <0.00513), and 
+2 log 2 ± 0.297 (p <0.00254), respectively (S1 Fig). BTK (+1.91 log 2 ± 0.309 
(p<0.0035)), CD4 (+1.86 log 2 ± 0.235 (p<0.00138)), HCK (+1.86 log 2 ± 0.304 
(p<0.00364)), PTPRC (+1.83 log 2 ± 0.259 (p<0.00211)), CCND3 (+1.67 log 2 ± 
0.337 (p<0.00777)), STAT1 (+1.59 log 2 ± 0.238 (p<0.00626)), IKBKE (+1.51 log 2 
± 0.282 (p< 0.00585)), IRF8 (+1.43 log 2 ± 0.246 (p<0.00439)), TNFRF1A (+1.39 
log 2 ± 0.298 (p<0.00954)), TLR2 (+1.34 log 2 ± 0.147 (p<0.000799)), BAX (+1.31 
log 2 ± 0.246 (p<0.00598)), IRF5 (+1.27 log 2 ± 0.193 (p<0.00272)), PNMA1 
(+0.986 log 2 ± 0.201 (p<0.00799)), ANP32B (+0.92 log 2 ± 0.163 (p<0.00484)), 
TFE3 (-0.37 log 2 ± 0.0783 (p<0.00919)), and mRNA also showed statistically 
significant (p <0.01), but less than twice log 2, differential expression between 
pancreatic adenocarcinomas with good and worse prognosis (Table 2). 
Gene expression analysis indicated that the PC group with a good prognosis showed 
higher levels of the following cell types compared to the group with a worse 
prognosis (Figures 3–5): CD45-expressing cells, Tregs, DCs, macrophages, NK 
CD56dim cells, T cells, exhausted CD8+ cells, cytotoxic cells, mast cells, CD8+ T 
cells and neutrophils (Figures 3 and 4). Box plot representations indicate that the 
following subtypes of cells exhibit particularly different levels: CD45-expressing 
cells, dendritic cells, macrophages, natural killer cells, the family of T cells (Figure 
5), and exhausted CD8+ and Treg cells (Figures 6-8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2. Differential gene expression between “good prognosis cases” and “worse prognosis 
cases” of PC. Volcano plot in which the larger red dots represent only those genes whose 
expression is at least twice log2 higher in “good cases” (Group B) relative to “worse cases” (Group 
A) with p-value < 0.01. Genes with highly statistically significant differential expression fall at the 
top of the plot above the horizontal lines, and highly differentially expressed genes fall to either side 
depending on whether they are negatively or positively differentially expressed. Horizontal lines 
indicate various False Discovery Rate (FDR) thresholds or p-value thresholds if there is no 
adjustment to the p-values. Genes are red if the resulting p-value is below the given FDR or p-value 
threshold. The 20 genes showing the most statistically significant differential expression are 
labelled in the plot.  
 
 
 
 
 
 
 
 
 
 
  
Table 2. Top 20 genes differentially expressed between “good cases” and “worse cases”. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Tumour immune cell profiling by immunohistochemical analysis. Trend plot 
summarizing the change in abundance of cell types from “worse cases” (A) to “good cases” (B). 
 
 
 
 
 
 
 
 
Genes Differential expression between 
“good cases” and “worse cases” 
(log2 fold change) 
Std error P-Value 
TLR7-mRNA 2.76 0.58 0.00896 
TNF-mRNA 2.39 0.389 0.00356 
C1QA-mRNA 2.19 0.43 0.00697 
FOXP3-mRNA 2.07 0.372 0.00513 
CD37-mRNA 2 0.297 0.00254 
BTK-mRNA 1.91 0.309 0.0035 
CD4-mRNA 1.86 0.235 0.00138 
HCK-mRNA 1.86 0.304 0.00364 
PTPRC-mRNA 1.83 0.259 0.00211 
CCND3-mRNA 1.67 0.337 0.00777 
STAT1-mRNA 1.59 0.238 0.00262 
IKBKE-mRNA 1.51 0.282 0.00585 
IRF8-mRNA 1.43 0.246 0.00439 
TNFRSF1A-mRNA 1.39 0.298 0.00954 
TLR2-mRNA 1.34 0.147 0.000799 
BAX-mRNA 1.31 0.246 0.00598 
IRF5-mRNA 1.27 0.193 0.00272 
PNMA1-mRNA 0.986 0.201 0.00799 
ANP32B-mRNA 0.92 0.163 0.00484 
TFE3-mRNA -0.37 0.0783 0.00919 
 Figure 4. Heat map showing the levels of the different cell types in “worse cases” (pink) and 
“good cases” (grey). Yellow-orange indicates high abundance, blue indicates low abundance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 5. Box plots. Box plots of measurements of CD45-expressing cells, dendritic cells, 
macrophages, NK, and T cells, in “good cases” (B) and “worse cases” (A). 
 
 
 
 
 
 
 Figure 6. Differential gene expression between the good and worse prognosis PDAC patient 
groups. Volcano plot displaying each gene's -log10 (p-value) against log2 fold change: a) TLR7, b) 
TNF, c) C1QA, d) FOXP3 and e) CD37. Highly statistically significant genes fall at the top of the 
plot, and highly differentially expressed genes fall to either side. Genes within the selected gene set 
are highlighted in orange. Horizontal lines indicate various False Discovery Rate (FDR) thresholds. 
 
 
 
 Figure 7. Exhausted CD8+ and Treg cell profiling in pancreatic adenocarcinomas with good versus 
worse prognosis. Box plots show levels of exhausted CD8+ cells (a) and Tregs (b) in patients with 
worse prognosis (group A) and patients with worse prognosis (group B). Even though scores seem 
overlapping, the average score for both sets of cells is higher in group B than in group A, probably 
due to the fact that longer-surviving PDAC patients had higher levels of intratumoral TILs. 
 
Figure 8. Relative cell type abundance measurements between group A and B. The diagram shows 
the abundance of exhausted CD8+ cells and Tregs compared to levels of CD8+ cells. In agreement 
with the previous figure, levels of exhausted CD8+ cells (green line) and Tregs (dashed orange line) 
are reported to be lower in the group with a worse prognosis (group A) than in the group with a 
better prognosis (group B) when compared with the total level of CD8+ cells. 
 
 
 
Tumour immune cell profiling in pancreatic adenocarcinomas with good 
versus worse prognosis 
Tumour immune cell marker levels were higher in good prognosis cases compared to 
worse prognosis cases (Table 3). The CD3 level was statistically higher in the good 
prognosis group compared to the worse prognosis group (p = 0.0267, Table 4), 
(Figure 9). Despite the fact that the number of CD8+ and CD20+ cells has been 
found to be higher in patients with good prognosis in our study, no statistically 
significant difference was found between the two subgroups of immune cells (p = 
0.119 and p = 0.925, respectively) (Table 4), (Figure 9). TIL marker levels were not 
assessed in one case due to calcification in pancreatic ductal tissue. Figure 10 shows 
the detection of TILs in the two sets of six PC patients. Staining for TILs was visually 
negative in the adenocarcinomas with a worse prognosis while it was positive for the 
adenocarcinomas with a good prognosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Levels of CD3, CD8 and CD20 TIL subpopulations. Data are reported as a percentage 
value of stroma TILs and are related to the sub-group assessed (CD3, CD8, CD20). For every 
antigen, two columns of values are reported, each corresponding to a different pathologist’s 
evaluation. The final score has been given in a semi-quantitative way by evaluating cell density in 
10 digital images (20x enlargement) and calculating the average of all scores. The scores have been 
given following the guidelines of the “International TILs Working Group 2014”. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Statistical difference of TIL levels between the two groups. The table summarizes the 
statistical difference of TIL levels between the “worse case” and “good case” groups (non-
parametric Mann Whitney test or “U-test”). 
 
 Median “worse cases” Median “good cases” p-value 
 N. pts   N. pts     
CD3 5 7 (6.5-12) 6 12.25 (9-35) 0.0267 
CD8 5 7 (2-13) 6 9.25 (4-14) 0.119 
CD20 5 1.5 (0-2.5) 6 1.5 (0-4.5) 0.925 
 
Sample 
number 
CD3 CD8 CD20 
Worse cases 
1 6 7 5 9 1 2 
2 Not performed 
3 13 11 10 6 2 3 
4 9 8 13 13 1 2 
5 9 4 3 4 2 3 
6 9 5 1 3 0 0 
Good cases 
1 10 8 10 9 2 3 
2 10 8 5 3 0 1 
3 23 16 6 12 0 0 
4 10 8 10 8 0 1 
5 27 16 15 13 5 4 
6 16 15 15 11 2 3 
 Figure 9. Levels of TIL markers in “worse cases” (Worse) and “good cases” (Good) of pancreatic 
adenocarcinoma. The box plots represent the expression levels of CD3, CD8 and CD20 TIL 
subpopulations comparing the “worse case”and “good case” groups. The lower table summarizes 
the statistical difference of TIL levels between the “worse case”and “good case” groups (non-
parametric Mann Whitney test or “U-test”). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. TILs stained for CD3 expression across the two groups of patients. Samples A-E were 
collected from “worse cases”, samples F-K from “good cases”. 
 
Discussion 
The role of immune system in cancer progression has been widely investigated, to 
date we known that PCs tend to recruit immunosuppressive cells including myeloid-
derived suppressor cells (MDSCs), regulatory T cells (Tregs) and tumour-associated 
macrophages (TAMs). Pancreratic cancers also inhibit immune effector cells, mainly 
CD4+ CD8+ T lymphocytes, natural killer (NK) cells and dendritic cells (DCs). 
Some PCs, moreover, overexpress programmed death ligand 1 (PDL1) and secrete 
inhibitory cytokines such as interleukin 10 (IL10) and tumour growth factor β 
(TGFβ).  The correlation between TILs and clinical outcomes has been investigated 
in several studies involving PC patients. Patients with CD4+ tumours were found to 
have OS and DFS higher than patients with CD4- tumours but no significant 
correlation was found between CD8+ TILs and survival or other clinical-pathological 
features. The tumour microenvironment of PC has been consistently reported to be 
capable of promoting immune escape, rendering the immune system ineffective in 
eliciting an anti-tumour response. Improved understanding of the tumour 
microenvironment and how it contributes to immune evasion could, therefore, lead to 
better treatments and outcomes for PC patients. Unfortunately, first data about 
immunotherapy are still controversial without any clear efficacy for novel 
immunocheckpoints inhibitors.  There are three major barriers impeding immune 
therapy in PC: 1. The mutational load in PC is much lower than that of lung cancers 
and melanoma; 2. PC has a strong immunosuppressive microenvironment which is 
composed of a dense desmoplastic reaction having remarkable infiltration of 
tumourigenic MDSCs and macrophages; 3. The PC microenvironment has a very low 
number of infiltrating T cells, insufficient to provide a significant T cell response. In 
the current study, PC samples from patients with a good prognosis had higher levels 
of TILs compared to a group of patients with a worse prognosis, as assessed via 
immune marker levels. Even though the patient numbers are small and the selection 
of good prognosis or worse prognosis somewhat arbitrary (based on clinical data and 
Kaplan-Meier curves) (Figure 1), the correlation is consistent with previous reports 
suggesting that TIL levels provide a robust predictor of outcome in pancreatic cancer. 
Consistent with data reported by Stromness et al, we point out that in some samples 
of the “Good” prognosis group, CD3+ cells tend to organise in tertiary lymphoid 
structures (TLS) within tumour stroma. Although there is limited knowledge of TLS, 
these formations are commonly found in solid tumour with a better prognosis, 
suggesting their possible role in T cell regulation of in-situ immune response. 
Furthermore, our study revealed a significant (p-value <0.001) differential expression 
of 20 immune system genes between PC patients with good and worse prognoses. 
Among these genes, the expression of five (TLR7, TNF, C1QA, FOXP3, CD37) was 
at least twice log 2 higher in the good prognosis group relative to the worse prognosis 
group. Expression levels of these five genes could constitute a molecular signature of 
likely outcome and could therefore be useful for clinical applications. FOXP3 is a 
well known marker of Tregs, with a pivotal role in the development and 
differentiation of these cells to promote tumour immune escape. Conversely, FOXP3 
has been reported to be an important tumour suppressor gene in breast cancer, gastric 
adenocarcinoma, prostate cancer, and non-small cell lung cancer. These findings 
indicate that the roles of FOXP3 in tumours are diverse and situation-dependent. 
C1QA encodes the A-chain polypeptide of complement subcomponent C1q and plays 
an important role in counteracting tumour cells. Teschendorff and Caldas et al 
showed that overexpression of C1QA in ER-negative basal-like breast cancer patients 
is associated with better prognosis. It was shown more recently that lower C1QA 
expression could be linked with worse outcomes in patients with ER-negative breast 
cancer. Nonetheless, Bulla et al recently showed that C1q can exert functions 
unrelated to complement activation, contributing to extracellular changes within the 
tumour microenvironment and supporting tumour growth and invasion. This last 
finding is supported by Winslow et al. 
TNF has long been considered a key regulator of the inflammatory and immune 
response to cancer, promoting either death or survival under different circumstances. 
Although several anti-TNF therapies have been developed with different binding and 
pharmacokinetic profiles, TNF is used in current therapies to fight cancer, 
notwithstanding its toxicity. TNF has proved to have an effect on metastatic 
melanoma treatment and unresectable soft tissue therapies. There is evidence of 
TNF’s role in promoting regression of unresectable hepatic metastasis from 
colorectal cancer and in causing tumour necrosis via its pro-coagulant effect. TLR7 is 
of special interest in cancer therapy on account of its strong stimulation of IL-12 and 
type-I interferons, which are important cytokines and effectors of T and NK cell 
functions. TLR7 ligands can not only activate directly NK cells and cytotoxic T-cells, 
but also hamper the suppressive function of myeloid-derived suppressor cells and 
interfere with the migration of Tregs into the tumour. TLR agonists are clinically 
approved or under clinical evaluation for cancer immunotherapy. CD37 belongs to 
the tetraspanin superfamily of transmembrane proteins that regulate protein adhesion, 
trafficking, and migration and that are emerging controllers of both humoral and 
immune control, especially stimulating dendritic cell migration and B cell survival. 
The contribution of CD37 to antitumour immunity has been known since the finding 
that CD37-/- mice have impaired antitumour responses; however, the role of CD37 in 
the tumour microenvironment is not clear and further investigations are needed. 
Tetraspanins in the tumour microenvironment may have therapeutic potential via 
stimulation or inhibition of immune cell functions, depending on the immune cell 
type.  
Several studies have identified biomarkers that could be used as predictors of clinical 
outcome for PC, but none of these involves the immune-related gene signature 
revealed here. The key findings from this study, that longer-surviving PC patients had 
higher levels of intratumoural TILs and overexpressed five immune markers (TLR7, 
TNF, C1QA, FOXP3, CD37), could have two main uses. Firstly, TIL levels and 
marker gene panel expression could be used for clinical outcome prediction, 
stratification and treatment design for PC patients. A previous study showed that a 
signature comprising another 15 genes was an independent prognostic factor in two 
cohorts of PC patients. In contrast to our results, higher expression of these 15 genes 
was associated with poor OS. Similarly, Sergeant et al identified high co-expression 
of TGF-β1 and a panel of cell motility genes as independent predictors of 
worse clinical outcome, while Van den Broek et al discovered that high expression of 
ABCB1 and CXCR4 correlated with worse clinical outcome. Furthermore, decreased 
levels of DPEP1 and increased expression of TPX2 were independently associated 
with poor survival. Presumably, a wide panel of validated gene signatures would be 
most useful for outcome prediction, stratification and therapeutic decision making. 
Secondly, our findings could be useful in developing new PC treatments, for example 
in combination with current immunotherapeutic strategies. Expression of the target 
genes identified here could be induced together with therapies modulating the tumour 
microenvironment to relieve immunosuppression, and/or approaches to break down 
the desmoplastic barrier surrounding PC to facilitate target access for infiltrating T 
cells or therapeutic molecules. Such strategies could be effected in combination with 
recently reported gene therapy and oncologic vaccination approaches. In summary, 
our data indicate that a gene signature comprising at least TLR7, TNF, C1QA, 
FOXP3, and CD37 could be useful to improve the prediction of OS in PC patients. 
Together with an assessment of TIL levels, such an immune system gene panel 
constitutes a potential prognostic tool to permit a risk-based stratification of 
pancreatic tumour patients into personalized treatment protocols towards improving 
the current abysmal clinical outcome of these patients. 
 
Future Perspective 
 
The findings in the paper might be useful in stratifying patients and indicating the 
best treatment available for pancreatic cancer patients. In addition, our study could 
pave the way for finding novel targets for the development of new drugs for this 
disease. 
 
 
 
Summary Points 
1. Pancreatic carcinoma (PC) has a very poor prognosis. 
2. Due to its fibroblastic reaction, PC is poorly antigenic and relatively sparsely infiltrated by 
immune cells. 
3. Tumour-infiltrating lymphocytes (TILs) can influence PC prognosis. 
4. Twelve patients with PC and different outcomes exhibited  different infiltration of tumour 
infiltrating lymphocytes: lymphocyte infiltration was markedly higher in patients with a 
better prognosis. 
5. Six PC patients with different outcomes showed a different gene expression signature: three 
patients with good prognosis showed statistically significant differential expression of 20 
immune-related genes relative to three patients with a worse prognosis. 
6. Among these 20 immune system-related genes, FOXP3, C1QA, TNF, TLR7, CD37 were 
found to have at least twice log 2 higher expression in PDAC patients with a better outcome. 
7. This gene panel could be induced to break down the desmoplastic barrier and facilitate 
access of TILs or therapeutic drugs. 
8. Together with TIL assessment, this immune gene signature could be a useful prognostic tool 
for the stratification of PC patients and could be used in combination with current 
immunotherapeutic strategies. 
9. Personalised treatment and precision medicine approaches are currently leading routes to 
improve treatment for PC patients. 
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